|
시장보고서
상품코드
1597063
북미의 약동학 서비스 시장 예측(-2031년)North America Pharmacokinetics Services Market Forecast to 2031 - Regional Analysis - by Drug Type, Service Type, Therapeutic Application, and End User |
||||||
북미의 약동학 서비스 시장은 2023년에 3억 7,536만 달러로 평가되었고, 2031년에는 6억 9,277만 달러에 이를 것으로 예측되며, 2023년부터 2031년까지의 CAGR은 8.0%로 추정됩니다.
약동학 연구의 활용 영역 확대가 북미 약동학 서비스 시장을 뒷받침
약동학 시험은 인간 등가 용량(HED) 수준, 관찰되지 않은 효과 수준(NOEL), 약동학/약력학적 시험 등 여러 매개변수를 결정하기 위해 채택되었습니다. 분석을 지원하는 것입니다. 일부 독성 학적 연구에서는 NOEL, 즉 부작용이 일어나지 않는 최고 용량에 대한 데이터가 수행되었습니다. 의약품 후보의 약동학 프로파일을 이해하는 것은 의약품 프로그램에서 중요한 역할을 합니다. PK 모델은 약물에 노출량 결정, 최적 복용량 분석을 위한 약물 농도 결정 및 인체에서 약물의 체내 역학 분석에 적용되는 경우가 많습니다. 치료 효과를 극대화하고 독성을 최소화하기 위해 PK의 원리를 도입했습니다.
북미의 약동학 서비스 시장 개요
북미의 약동학 서비스 시장에서 가장 큰 점유율을 차지하는 것은 미국입니다. 된 의료 인프라, 신속한 승인 인가 스케줄, 유리한 규제 틀이 이용 가능하기 때문에 제약 연구 기업이 임상시험을 실시하기 쉬운 환경이 갖추어져 있습니다. 또한 미국에서 실시된 임상시험에서 얻은 데이터는 세계적으로 받아들여지고 있습니다. 세계보건기구(WHO) 보고서에 따르면 미국은 2021년에 가장 많은 임상시험(157,618건)이 등록되었습니다.
북미의 약동학 서비스 시장의 수익과 2031년까지의 예측(단위: 100만 달러)
북미의 약동학 서비스 시장 내역
북미의 약동학 서비스 시장은 약물유형별, 서비스유형별, 치료 용도별, 최종 사용자별, 국가별로 분류됩니다.
약물유형별로, 북미의 약동학 서비스 시장은 저분자, 고분자, 백신으로 구분됩니다.
서비스 유형별로 북미의 약동학 서비스 시장은 전임상 ADME 및 인간 시험, PK/PD 분석 및 보고, 투여 시뮬레이션, 위험 분석 등으로 분류됩니다. 전임상 ADME 부문이 가장 큰 시장 점유율을 차지합니다.
치료 용도별로 북미의 약동학 서비스 시장은 암, 감염증, 신경질환, 자가면역질환, 부인과질환, 심혈관질환, 호흡기질환 등으로 구분됩니다. 2023년에는 종양학 부문이 가장 큰 시장 점유율을 차지했습니다.
최종 사용자별로 북미의 약동학 서비스 시장은 제약·바이오테크놀러지 기업, CRO, 기타에 구분됩니다.
국가별로 북미의 약동학 서비스 시장은 미국, 캐나다, 멕시코로 구분됩니다.
Charles River Laboratories International Inc, Eurofins Scientific SE, Evotec SE, Certara Inc, Parexel International Corp, Thermo Fisher Scientific Inc, Allucent, PACIFIC BIOLABS, SGS SA 등이 북미의 약동학 서비스 시장에서 사업을 전개하는 주요 기업입니다.
목차
제1장 서론
제2장 주요 요약
제3장 조사 방법
제4장 북미의 약동학 서비스 시장의 정세
- PEST 분석
제5장 북미의 약동학 서비스 시장 : 주요 시장 역학
- 시장 성장 촉진요인
- 만성 질환·감염증의 유병률의 상승
- 약동학 연구에의 응용 범위의 확대
- CRO에 대한 약동학 서비스의 아웃소싱
- 시장 성장 억제요인
- 신흥국에서의 약동학 서비스 업자의 범위 제약
- 시장 기회
- 약물동태의 편차를 이해하기 위한 생체내 및 생체외 모델의 채용 증가
- 향후의 동향
- 약동학 서비스에서 빅데이터 분석 채용 증가
- 성장 촉진요인과 저해요인의 영향
제6장 북미의 약동학 서비스 시장 분석
- 북미의 약동학 서비스 시장의 수익(2021-2031년)
제7장 북미의 약동학 서비스 시장 분석 : 약제 유형별
- 저분자
- 고분자
- 백신
제8장 북미의 약동학 서비스 시장 분석 : 서비스 유형별
- 전임상 ADME 및 인간 시험
- PK/PD 분석과 리포팅
- 투여 시뮬레이션
- 리스크 분석
- 기타
제9장 북미의 약동학 서비스 시장 분석 : 치료 용도별
- 암 영역
- 감염증
- 신경질환
- 자가면역질환
- 부인과 질환
- 순환기 질환
- 호흡기 질환
- 기타
제10장 북미의 약동학 서비스 시장 분석 : 최종 사용자별
- 제약·바이오테크놀러지 기업
- CRO(의약품 개발 업무 수탁 기관)
- 기타
제11장 북미의 약물동태 서비스 시장 : 국가별 분석
- 북미
- 미국
- 캐나다
- 멕시코
제12장 기업 프로파일
- Charles River Laboratories International Inc
- Eurofins Scientific SE
- Evotec SE
- Certara Inc.
- Parexel International Corp
- Thermo Fisher Scientific Inc.
- Allucent
- PACIFIC BIOLABS
- SGS SA
제13장 부록
JHS 24.12.04The North America pharmacokinetics services market was valued at US$ 375.36 million in 2023 and is expected to reach US$ 692.77 million by 2031; it is estimated to register a CAGR of 8.0% from 2023 to 2031.
Expanding Range of Application of Pharmacokinetic Studies Fuels North America Pharmacokinetics Services Market
Pharmacokinetic studies are being employed to determine several parameters such as human-equivalent doses (HED) level, no-observed effect level (NOEL), and pharmacokinetic/pharmacodynamic testing. The main focus of any pre-clinical program conducted is to support the analysis of a safe and effective dose range for testing in pharmacokinetic studies. Several toxicology studies conducted data on the NOEL, i.e., the highest dose that does not produce adverse effects. This dose level is further converted to a HED level on a comparative body-surface area basis if there is lack of clinical pharmacokinetic data. Understanding the pharmacokinetic profile of a potential drug candidate plays an important role in the drug discovery program. Regulatory authorities play a major role propelling the implementation of pharmacokinetic studies. These studies are also instrumental in optimizing pharmaceutical care services provided to patients admitted in hospitals. The PK model is often applied to determine exposure to drugs, concentrations of drugs to analyze optimal dosage, and analyze the disposition of drugs in the human body. Healthcare providers implement the principles of PK to design monitor drug concentrations, doses of some drugs, maximize the intended therapeutic outcomes and minimize toxicities.
North America Pharmacokinetics Services Market Overview
The US accounts for the largest share of the North America pharmacokinetics services market in North America. The country has emerged as a leading clinical research destination; it accounts for ~50% of the total clinical trials conducted in the world. The availability of established medical infrastructure, fast approval timelines, and favorable regulatory framework create a conducive environment for pharmaceutical research companies to conduct clinical trials. Moreover, the data generated in trials conducted in the US is accepted globally. As per a World Health Organization (WHO) report, the US registered the highest number of clinical trials (157,618) in 2021.
North America Pharmacokinetics Services Market Revenue and Forecast to 2031 (US$ Million)
North America Pharmacokinetics Services Market Segmentation
The North America pharmacokinetics services market is categorized into drug type, service type, therapeutic application, end user, and country.
Based on drug type, the North America pharmacokinetics services market is segmented small molecule, large molecule, and vaccines. The small molecule segment held the largest market share in 2023.
In terms of service type, the North America pharmacokinetics services market is categorized into pre-clinical ADME and human studies, PK/PD analysis and reporting, dosing simulations, risk analysis, and others. The pre-clinical ADME and human studies segment held the largest market share in 2023.
By therapeutic application, the North America pharmacokinetics services market is segmented into oncology, infectious diseases, neurological disorders, autoimmune diseases, gynaecological disorders, cardiovascular diseases, respiratory disorders, and others. The oncology segment held the largest market share in 2023.
By end user, the North America pharmacokinetics services market is segmented into pharmaceutical and biotechnology companies, contract research organization, and others. The contract research organization segment held the largest market share in 2023.
By country, the North America pharmacokinetics services market is segmented into the US, Canada, and Mexico. The US dominated the North America pharmacokinetics services market share in 2023.
Charles River Laboratories International Inc; Eurofins Scientific SE; Evotec SE; Certara Inc.; Parexel International Corp; Thermo Fisher Scientific Inc.; Allucent; PACIFIC BIOLABS; and SGS SA are some of the leading companies operating in the North America pharmacokinetics services market.
Table Of Contents
1. Introduction
- 1.1 The Insight Partners Research Report Guidance
- 1.2 Market Segmentation
2. Executive Summary
- 2.1 Key Insights
3. Research Methodology
- 3.1 Coverage
- 3.2 Secondary Research
- 3.3 Primary Research
4. North America Pharmacokinetics Services Market Landscape
- 4.1 PEST Analysis
5. North America Pharmacokinetics Services Market - Key Market Dynamics
- 5.1 Market Drivers
- 5.1.1 Rising Prevalence of Chronic and Infectious Diseases
- 5.1.2 Expanding Range of Application of Pharmacokinetic Studies
- 5.1.3 Outsourcing of Pharmacokinetics Services to CROs
- 5.2 Market Restraints
- 5.2.1 Limited Reach of Pharmacokinetics Service Providers in Emerging Countries
- 5.3 Market Opportunities
- 5.3.1 Increasing Adoption of In-Vivo and In-Vitro Models for Understanding Variability in Pharmacokinetics
- 5.4 Future Trend
- 5.4.1 Increasing Adoption of Big Data Analytics in Pharmacokinetics Services
- 5.5 Impact of Drivers and Restraints:
6. Pharmacokinetics Services Market - North America Analysis
- 6.1 North America Pharmacokinetics Services Market Revenue (US$ Million), 2021-2031
7. North America Pharmacokinetics Services Market Analysis - by Drug Type
- 7.1 Overview
- 7.2 Small Molecule
- 7.2.1 Overview
- 7.2.2 Small Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 7.3 Large Molecule
- 7.3.1 Overview
- 7.3.2 Large Molecule: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 7.4 Vaccines
- 7.4.1 Overview
- 7.4.2 Vaccines: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
8. North America Pharmacokinetics Services Market Analysis - by Service Type
- 8.1 Overview
- 8.2 Pre-Clinical ADME and Human Studies
- 8.2.1 Overview
- 8.2.2 Pre-Clinical ADME and Human Studies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 8.3 PK/PD Analysis and Reporting
- 8.3.1 Overview
- 8.3.2 PK/PD Analysis and Reporting: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 8.4 Dosing Simulations
- 8.4.1 Overview
- 8.4.2 Dosing Simulations: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 8.5 Risk Analysis
- 8.5.1 Overview
- 8.5.2 Risk Analysis: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 8.6 Others
- 8.6.1 Overview
- 8.6.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
9. North America Pharmacokinetics Services Market Analysis - by Therapeutic Application
- 9.1 Oncology
- 9.1.1 Overview
- 9.1.2 Oncology: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 9.2 Infectious Diseases
- 9.2.1 Overview
- 9.2.2 Infectious Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 9.3 Neurological Disorders
- 9.3.1 Overview
- 9.3.2 Neurological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 9.4 Autoimmune Diseases
- 9.4.1 Overview
- 9.4.2 Autoimmune Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 9.5 Gynecological Disorders
- 9.5.1 Overview
- 9.5.2 Gynecological Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 9.6 Cardiovascular Diseases
- 9.6.1 Overview
- 9.6.2 Cardiovascular Diseases: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 9.7 Respiratory Disorders
- 9.7.1 Overview
- 9.7.2 Respiratory Disorders: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 9.8 Others
- 9.8.1 Overview
- 9.8.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
10. North America Pharmacokinetics Services Market Analysis - by End User
- 10.1 Pharmaceutical and Biotechnology Companies
- 10.1.1 Overview
- 10.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 10.2 Contract Research Organization
- 10.2.1 Overview
- 10.2.2 Contract Research Organization: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 10.3 Others
- 10.3.1 Overview
- 10.3.2 Others: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
11. North America Pharmacokinetics Services Market - Country Analysis
- 11.1 North America
- 11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
- 11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.1.1.1.1 Overview
- 11.1.1.1.2 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.1.1.1.3 United States: North America Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.1.1.1.4 United States: North America Pharmacokinetics Services Market Breakdown, by Service Type
- 11.1.1.1.5 United States: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.1.1.1.6 United States: North America Pharmacokinetics Services Market Breakdown, by End User
- 11.1.1.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.1.1.2.1 Overview
- 11.1.1.2.2 Canada: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.1.1.2.3 Canada: North America Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.1.1.2.4 Canada: North America Pharmacokinetics Services Market Breakdown, by Service Type
- 11.1.1.2.5 Canada: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.1.1.2.6 Canada: North America Pharmacokinetics Services Market Breakdown, by End User
- 11.1.1.3 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.1.1.3.1 Overview
- 11.1.1.3.2 Mexico: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.1.1.3.3 Mexico: North America Pharmacokinetics Services Market Breakdown, by Drug Type
- 11.1.1.3.4 Mexico: North America Pharmacokinetics Services Market Breakdown, by Service Type
- 11.1.1.3.5 Mexico: North America Pharmacokinetics Services Market Breakdown, by Therapeutic Application
- 11.1.1.3.6 Mexico: North America Pharmacokinetics Services Market Breakdown, by End User
- 11.1.1.1 United States: North America Pharmacokinetics Services Market - Revenue and Forecast to 2031 (US$ Million)
- 11.1.1 North America Pharmacokinetics Services Market Breakdown, by Key Countries, 2023 and 2031 (%)
12. Company Profile
- 12.1 Charles River Laboratories International Inc
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
- 12.2 Eurofins Scientific SE
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
- 12.3 Evotec SE
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
- 12.4 Certara Inc.
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.5 Parexel International Corp
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
- 12.6 Thermo Fisher Scientific Inc.
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
- 12.7 Allucent
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments
- 12.8 PACIFIC BIOLABS
- 12.8.1 Key Facts
- 12.8.2 Business Description
- 12.8.3 Products and Services
- 12.8.4 Financial Overview
- 12.8.5 SWOT Analysis
- 12.8.6 Key Developments
- 12.9 SGS SA
- 12.9.1 Key Facts
- 12.9.2 Business Description
- 12.9.3 Products and Services
- 12.9.4 Financial Overview
- 12.9.5 SWOT Analysis
- 12.9.6 Key Developments
13. Appendix
- 13.1 About The Insight Partners
- 13.2 Glossary of Terms for Pharmacokinetic Services Market
